Skip to main content
3 April 2019
Last updated:
Tuesday 2 April 2019

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Commentary: Glybera- When the experts disagree

Tuesday 8 November 2011
Country

United Kingdom

The Committee for Advanced Therapies (CAT) was set up at the European Medicines Agency in 2009 in order to give expert advice on whether advanced therapy medicinal products should be approved or not. These therapies include gene and cell therapies and products engineered from human and/or animal tissue.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Regulation & Policy

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Pierluigi Paracchi receives innovation award
Friday March 22 2019
Dan Furrer to head marketing at Neuraxpharm
Sunday March 17 2019
Kiadis names Dirk de Naeyer as COO
Sunday March 17 2019
Pius Hornstein to head Sanofi China
Sunday March 17 2019
John Dellapa becomes general counsel at Neurimmune
Sunday March 17 2019

© 2019 Evernow Publishing Ltd. Powered by Drupal.